Energy Champion: PharmaBlock Earns ISO 50001
PharmaBlock Sciences (Nanjing), a global CRDMO company integrating chemistry research and development, recently achieved ISO 50001:2018 Energy Management System Certification for its headquarters, R&D centre in Nanjing, and manufacturing facilities in Zhejiang and Shandong, China.
This accomplishment underscores PharmaBlock's ongoing commitment to streamlined operations, energy efficiency, and sustainable practices.
The company has actively enhanced its energy management systems in alignment with The Paris Agreement and China’s Carbon Peaking and Carbon Neutrality Goals.
Adhering to ISO 50001 standards, PharmaBlock has systematically implemented measures to decrease energy consumption, greenhouse gas emissions, and other environmental impacts. As outlined in its inaugural ESG report from early 2023, PharmaBlock aims to achieve a 20% reduction in energy consumption by 2030, using 2022 as the baseline year.
In addition to efficient management practices, PharmaBlock's Technology Innovation Centre (TIC) functions as a focal point for exploring environmentally friendly and intelligent pharmaceutical manufacturing models.
The TIC has introduced a range of low-carbon technologies, including flow chemistry, micropacked bed hydrogenation, biocatalysis, and heterogeneous catalysis. By incorporating green chemistry design, process optimisation, and low-carbon technology integration, the TIC is driving PharmaBlock's commitment to sustainable development.
PharmaBlock was honoured with the prestigious 2023 ACS CMO Excellence in Green Chemistry Award, recognising the company's progress in low-carbon technology innovation. This accolade was granted for a project employing continuous flow processes to produce a crucial intermediate in API synthesis for various marketed and clinical drugs. This innovative approach resulted in significant reductions in energy consumption, waste production, workspace requirements, and labour operations.
PharmaBlock plans to further optimise energy-saving and emission-reduction initiatives across its operations to enhance efficiency and cut costs. The company will also uphold its dedication to green development, advocating for sustainable practices in the pharmaceutical R&D and manufacturing sector, aiming to create long-term value for customers, the industry, and society at large.
To view and compare company ESG Ratings and Sustainability Reports, visit our Company ESG Profiles page.